CRISPR powers everything from gene editing to rapid diagnostics, but how did one of its most versatile branches arise? A new Cell study, “Functional RNA splitting drove the evolutionary emergence of ...

People are still debating whether the mRNA from COVID-19 vaccines remains in the body longer than it should. Some say it lingers and causes harm, others say that idea just doesn’t hold up. A new ...

Tempus AI Inc (NASDAQ:TEM) shares are trading higher Monday morning after the company announced it has received U.S. Food and Drug Administration 510(k) clearance for its RNA-based Tempus xR IVD ...

KYOTO & FUJISAWA, Japan--(BUSINESS WIRE)--xFOREST Therapeutics Co., Ltd. (“xFOREST”) and Axcelead Drug Discovery Partners, Inc. (“Axcelead DDP”) today announced the launch of a joint research ...

Clear visuals can make complicated ideas easier to understand, and Microsoft Visio Professional 2024 is designed to help you create them. Right now, you can get a lifetime license for Windows for ...

Human-based genetic editing systems — as opposed to bacteria-based editing systems like CRISPR — have less potential for issues. Photo credit: iStock Genetic editing holds promise to treat incurable ...

Two biotech leaders, John Maraganore and Clive Meanwell, are embarking on what Maraganore is calling their third act together: a new start-up called Corsera Health. Their first act together, as ...

São Pedro de Alcântara St. Upper stop BAIRRO ALTO Glória walk Where carriage crashed Lower stop The vintage Lisbon funicular that crashed on Wednesday, killing at least 16 people, lost control when ...

Deep learning methods have demonstrated great performance for RNA secondary structure prediction. However, generalizability is a common unsolved issue on unseen out-of-distribution RNA families, which ...

Article subjects are automatically applied from the ACS Subject Taxonomy and describe the scientific concepts and themes of the article. For fluorescence-based applications, RNA aptamers can be ...

Arnatar Therapeutics has unveiled with $52 million in series A financing to bankroll new RNA-based therapies, including a candidate that takes aim at a rare genetic disease called Alagille syndrome ...

Donidalorsen is the first RNA-targeted prophylactic treatment approved for hereditary angioedema, offering significant attack rate reduction. The OASIS-HAE study showed an 81% reduction in HAE attacks ...